

# FTGF Putnam Global Healthcare Fund

PR EUR DIS (A): IE00063WZZG3

Sector | Factsheet as of 30 November 2025

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.

## Investment Overview

To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of healthcare-related companies (companies that operate in, or are related to, the major subsectors of the healthcare sector, including pharmaceuticals, biotechnology, healthcare technology, life sciences tools and services, healthcare equipment and supplies, and healthcare providers and services).

## Performance

Under current legislation, we are not allowed to display performance data with less than a complete 12 month performance record.

## Fund Overview

Umbrella	Franklin Templeton Global Funds plc
Fund Base Currency	USD
Fund Inception Date	30/05/2025
Share Class Inception Date	30/05/2025
Dividend Frequency	Annually
Minimum Investment	EUR 7500000
ISIN	IE00063WZZG3
Bloomberg	FPGHPED ID
Morningstar Peer Group	Sector Equity Healthcare
EU SFDR Category	Article 8

## Benchmark(s) and Type

MSCI World Health Care Index-NR	Comparator
---------------------------------	------------

## Charges

Maximum Initial Charge	0.00%
Exit Charge	—
Ongoing Charges Figure	0.80%
Performance Fee	—

The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

## Fund Characteristics

Fund	
NAV-PR EUR DIS (A)	€117.93
Total Net Assets (USD)	\$3.83 Million
Number of Issuers	38
Average Market Cap (Millions USD)	\$292,053
Price to Book	6.13x
Price to Earnings (12-Month Forward)	21.23x

**Top Equity Issuers (% of Total)**

	Fund
Eli Lilly	9.67
Johnson & Johnson	7.77
AbbVie	6.96
AstraZeneca	5.14
UnitedHealth	5.03
Thermo Fisher Scientific	4.63
Novartis	4.50
Merck	4.37
Intuitive Surgical	3.48
Medtronic	3.26

**Portfolio Management**

	Years with Firm	Years of Experience
Mike Maguire, CFA	16	23

**What are the Risks?**

The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: **Investment in company shares:** The fund invests in shares of companies, and the value of these shares can be negatively affected by changes in the company, its industry or the economy in which it operates. **Fund operations:** The fund is subject to the risk of loss resulting from inadequate or failed internal processes, people or systems or those of third parties such as those responsible for the custody of its assets, especially to the extent that it invests in developing countries. **Sustainability:** The fund's integration of sustainability risks in the investment decision process may have the effect of excluding profitable investments from the investment universe of the fund and may also cause the fund to sell investments that will continue to perform well. A sustainability risk could materialise due to an environmental, social or governance event or condition which may impact the fund's investments and negatively affect the returns of the fund. **Concentrated fund:** The fund invests in fewer companies than other funds which invest in shares usually do. This means that the fund does not spread its risk as widely as other funds and will therefore be affected more if an individual company has significant losses. **Emerging markets investment:** The fund may invest in the markets of countries which are smaller, less developed and regulated, and more volatile than the markets of more developed countries. **Derivatives:** The use of derivatives can result in greater fluctuations of the fund's value and may cause the fund to lose as much as or more than the amount invested. Complete information on the risks of investing in the Fund are set out in the Fund's prospectus.

**Glossary**

**Ongoing Charges Figure (OCF):** The Ongoing Charges Figure (OCF) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The OCF is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The OCF does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, where applicable, see the KID. For funds that lack 12 months of data, or for which OCF is not likely to give a fair idea of likely future costs, the figure shown is an estimate. **Comparator:** Benchmark is used for comparing Fund performance, but is not a constraint to Fund Investment. **Weighted Average Market Capitalization:** A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-month Forward):** A measure of the price to earnings ratio for a stock using the forecasted earnings for the next 12 months. For a portfolio, the value represents a weighted average of the stocks it holds.

**Portfolio Data Information**

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

**Geographic Allocation (% of Total)**

	Fund	Benchmark
United States	75.91	71.99
United Kingdom	6.33	5.44
Switzerland	5.42	8.60
Denmark	4.15	2.36
Japan	1.77	3.66
Netherlands	1.19	1.08
Belgium	0.95	0.49
France	0.00	2.88
Others	0.00	3.49
Cash & Other Net Assets	4.29	0.00

**Market Cap Breakdown (% of Total) (USD)**

	Fund
Less than \$1.4B	0.44
\$1.4B - \$5.2B	3.41
\$5.2B - \$30.6B	3.65
\$30.6B - \$130.7B	21.74
Over \$130.7B	66.47
Cash and other assets	4.29

**Important Information**

This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.

Further information in relation to the sustainability-related aspects of the Fund can be found at [www.franklintempleton.lu/SFDR](http://www.franklintempleton.lu/SFDR). Please review all of the Fund's objectives and characteristics before investing. This material is intended to be of general interest only and should not be construed as investment advice. It does not constitute legal or tax advice and it is not an offer for shares or an invitation to apply for shares of the Irish-domiciled Franklin Templeton Global Funds plc (the "Fund" or "FTGF"). For the avoidance of doubt, if you decide to invest, you will be buying units in the Fund and will not be investing directly in the underlying assets of the Fund.

Franklin Templeton ("FT") provides no guarantee or assurance that the Fund's investment objective will be attained. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. **Past performance does not predict future returns.** Currency fluctuations may cause the value of a Fund's investments to diminish or increase.

FT shall not be liable to any user of this document or to any other person or entity for the inaccuracy of information or any errors or omissions in its contents, regardless of the cause of such inaccuracy, error or omission. Any opinions expressed are the author's at publication date and they are subject to change without prior notice. Any research and analysis contained in this material has been procured by FT for its own purposes and is provided to you only incidentally. Data from third party sources may have been used in the preparation of this document and FT has not independently verified, validated or audited such data.

No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for public distribution in all jurisdictions and prospective investors, who are not financial professionals, should consult their financial advisor before deciding to invest. The Fund may use financial derivatives or other instruments which may entail specific risks more fully described in the Fund's Documents.

Subscriptions to shares of the Fund should only be made based on the Fund's current Prospectus and, where available, the relevant KID, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. These documents can be found on our website at [www.franklinresources.com/all-sites](http://www.franklinresources.com/all-sites), obtained, free of charge, from FTGF's registered office at Riverside Two, Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2, Ireland, or can be requested via FT's European Facilities Service which is available at <https://www.eifs.lu/franklintempleton>. The Fund's documents are available in English, French, German, Italian and Spanish.

In addition, a Summary of Investor Rights is available from [www.franklintempleton.lu/summary-of-investor-rights](http://www.franklintempleton.lu/summary-of-investor-rights). The summary is available in English.

The sub-funds of FTGF are notified for marketing in multiple EU Member States under the UCITS Directive. FTGF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

**Benchmark(s)** MSCI World Health Care Index. The Benchmark is used for performance comparison purposes and is considered by the Investment Manager in portfolio construction and monitoring investment risk.

The Fund is actively managed and may deviate materially from that of the benchmark(s).

**Intended retail Investor** Investors who understand the risks of the Fund and plan to invest for at least 5 years. The Fund may appeal to investors who are looking for long-term investment growth, are interested in exposure to equity markets of healthcare companies as part of a diversified portfolio, have a high risk profile and can tolerate significant short-term changes in the share price.

**Product availability** The Fund is available to all investors with at least basic investment knowledge, through a wide range of distribution channels, with or without the need for advice.

**CFA®** and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at [www.franklintempletondatasources.com](http://www.franklintempletondatasources.com). Source: MSCI makes no warranties and shall have no liability with respect to any MSCI data reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Net Returns (NR) include income net of tax withholding when dividends are paid.

**In Europe** (excluding UK & Switzerland), this financial promotion is issued by Franklin Templeton International Services S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg - Tel: +352-46 66 67-1 - Fax: +352 342080 9861. **In Switzerland**, issued by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selvastrasse 16, 8002 Zurich. **In the Middle East**, provided by Franklin Templeton Investments (ME) Limited, authorized and regulated by the Dubai Financial Services Authority. Franklin Templeton Investments, The Gate, East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E, Tel: +9714-4284100 Fax: +971 342080 9871. **In Canada**, this material may be distributed in Canada by Franklin Templeton Investments Corp.

Please visit [www.franklinresources.com/all-sites](http://www.franklinresources.com/all-sites) to be directed to your local Franklin Templeton website.

For further information on paying agents and representative agents of FTGF, please refer to the Fund's Prospectus.